Tokyo Tape
Sign in
← PeptiDream

Half-year report · Q2

4587.TEDINET S100WHGM
Period2025-01-01 → 2025-06-30
Filed2025-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥8.5bn2025-01-01 → 2025-06-30Cons.Revenue IFRS
Revenue¥46.7bn2024-01-01 → 2024-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥36.1bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Operating income−¥2.6bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Operating income¥24.6bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Profit before tax−¥2.9bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Profit before tax¥20.9bn2024-01-01 → 2024-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥24.7bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Net income¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Total assets¥78.5bnat 2025-06-30Cons.Assets IFRS
Total assets¥92.8bnat 2024-12-31Cons.Assets IFRS
Total assets¥95.9bnat 2024-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥24.9bnat 2025-06-30Cons.Liabilities IFRS
Total liabilities¥36.0bnat 2024-12-31Cons.Liabilities IFRS
Net assets / equity¥53.7bnat 2025-06-30Cons.Equity IFRS
Net assets / equity¥56.8bnat 2024-12-31Cons.Equity IFRS
Net assets / equity¥58.8bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31vCons.Equity IFRS
Equity (owners)¥53.7bnat 2025-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥56.8bnat 2024-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥58.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥33.3bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥48.1bnat 2024-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥25.5bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow−¥11.0bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥23.8bn2024-01-01 → 2024-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥2.7bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥8.4bn2024-01-01 → 2024-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥10.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.5bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥3.0bn2024-01-01 → 2024-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-16.42025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥115.852024-01-01 → 2024-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥138.32024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-16.42025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥115.682024-01-01 → 2024-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥138.112024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio68.3%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.2%at 2024-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.3%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥453m
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥453m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥761m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥761m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥3.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥8.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥453m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2025-01-01 → 2025-06-30¥436m
—segment totalrevenue2025-01-01 → 2025-06-30¥9.0bn
—segment totalrevenue external2025-01-01 → 2025-06-30¥8.5bn
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥453m
—segment totalsegment profit2025-01-01 → 2025-06-30−¥2.6bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥178m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥178m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥24.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥7.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥178m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥47m
—segment totalrevenue2024-01-01 → 2024-06-30¥36.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥36.1bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥178m
—segment totalsegment profit2024-01-01 → 2024-06-30¥24.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 582
ItemContextValueUnit
Profit loss IFRSPrior1YTDDuration17925302000JPY
Profit loss IFRSCurrentYTDDuration-2122490000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration17925302000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration-2122490000JPY
Profit loss IFRSPrior1YTDDuration17925302000JPY
Profit loss IFRSCurrentYTDDuration-2122490000JPY
Basic earnings loss per share IFRSPrior1YTDDuration138.30
Basic earnings loss per share IFRSCurrentYTDDuration-16.40
Diluted earnings loss per share IFRSPrior1YTDDuration138.11
Diluted earnings loss per share IFRSCurrentYTDDuration-16.40
Profit loss IFRSPrior1YTDDuration17925302000JPY
Profit loss IFRSCurrentYTDDuration-2122490000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration469448000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration－JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration469448000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration－JPY
Other comprehensive income IFRSPrior1YTDDuration469448000JPY
Other comprehensive income IFRSCurrentYTDDuration－JPY
Comprehensive income IFRSPrior1YTDDuration18394750000JPY
Comprehensive income IFRSCurrentYTDDuration-2122490000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration18394750000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration-2122490000JPY
Comprehensive income IFRSPrior1YTDDuration18394750000JPY
Comprehensive income IFRSCurrentYTDDuration-2122490000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember3956738000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember4550372000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-1085546000JPY
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember27804689000JPY
Equity IFRSPrior2YearInstant_OtherComponentsOfEquityIFRSMember5123456000JPY
Equity IFRSPrior2YearInstant_EquityAttributableToOwnersOfParentIFRSMember40349709000JPY
Equity IFRSPrior2YearInstant40349709000JPY
Profit loss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember17925302000JPY
Profit loss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember17925302000JPY
Profit loss IFRSPrior1YTDDuration17925302000JPY
Other comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember469448000JPY
Other comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember469448000JPY
Other comprehensive income IFRSPrior1YTDDuration469448000JPY
Comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember17925302000JPY
Comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember469448000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass